2 hours ago
1
asbe/iStock via Getty Images
Amneal Pharmaceuticals (NASDAQ:AMRX) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its generic product targeting Jazz Pharmaceuticals’ (NASDAQ:JAZZ) sleep disorder therapy Xyrem.
The approval of Amneal’s (NASDAQ:AMRX) Abbreviated New Drug Application (ANDA) allows the market entry of
English (US) ·